ILiAD Biotechnologies

This RA Capital Management article is a must read.

#whoopingcough #pertussis #biotech #vaccines #innovation #racapital

We believe an intranasal spray vaccine that holds the potential to prevent disease while at the same time halting transmission will be a game-changer in the fight against pertussis. 2/2

#whoopingcough #pertussis #biotech #vaccines #innovation

U.S. records most whooping cough deaths since 2017 Pertussis cases are on the rise again, after a dip following the winter holidays.

In light of rising whooping cough rates, we continue to press forward with our lead candidate BPZE1, the most advanced next-gen pertussis vaccine in development. 1/2

The ILiAD team is proud to be nominated for the Best Prophylactic Vaccine Award by the Vaccine Industry Excellence Awards in DC. Voting is open terrapinn-awards.evessiocloud.com/vieawards202.... Please feel free to share.

#whoopingcough #pertussis #biotech #vaccines #innovation

ILiAD and hVIVO Sign LOI for Pivotal Phase 3 Trial of BPZE1 Pertussis Vaccine Following FDA Meeting ILiAD Biotechnologies, LLC, a biotech company developing BPZE1, the most advanced next generation intranasal pertussis vaccine to protect against whoo

We are pleased to announce that we have signed a Letter of Intent with hVIVO for a pivotal phase 3 trial of BPZE1 pertussis vaccine following an FDA meeting.
 
www.businesswire.com/news/home/20...
 
#whoopingcough #pertussis #biotech #vaccines #innovation